8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 17, 2026·SEC
Bicycle Therapeutics plc(BCYC)Earnings, Financials & Key Ratios
BCYC•NASDAQ
Price updated Jun 19, 2026
AboutBicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Show more
- Revenue$73M+105.8%
- EBITDA-$241M-19.0%
- Net Income-$219M-29.5%
- EPS (Diluted)-3.16-9.0%
- Gross Margin100%+125.6%
- EBITDA Margin-332.43%+42.1%
- Operating Margin-341.28%+42.6%
- Net Margin-301.66%+37.0%
- ROE-31.21%-7.5%
BCYC Key Insights
Bicycle Therapeutics plc (BCYC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 47.5%
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Profits declining 33.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Shares diluted 19.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BCYC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BCYC Price & Volume
Bicycle Therapeutics plc (BCYC) stock price & volume — 10-year historical chart
Loading chart...
BCYC Growth Metrics
Bicycle Therapeutics plc (BCYC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years47.52%
3 Years71.21%
TTM146.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-7.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-0.64%
Return on Capital
10 Years-47.45%
5 Years-31.27%
3 Years-34.88%
Last Year-31.96%
BCYC Recent Earnings
Bicycle Therapeutics plc (BCYC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.87-67.3%
$0.52
Rev
$900,000-88.0%
$8M
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$0.29+69.1%
$0.94
Rev
$48M+581.6%
$7M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.85+22.0%
$1.09
Rev
$12M+65.8%
$7M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$1.14-20.0%
$0.95
Rev
$3M-65.2%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.87vs $0.52-67.3% | $900,000vs $8M-88.0% |
| Q2 2026 | Mar 17, 2026 | $0.29vs $0.94+69.1% | $48Mvs $7M+581.6% |
| Q4 2025 | Oct 30, 2025 | $0.85vs $1.09+22.0% | $12Mvs $7M+65.8% |
| Q3 2025 | Aug 8, 2025 | $1.14vs $0.95-20.0% | $3Mvs $8M-65.2% |
Based on last 12 quarters of dataView full earnings history →
BCYC Peer Comparison
Bicycle Therapeutics plc (BCYC) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PEPG | 123.81M | 1.79 | -0.84 | -59.89% | 0.12 | |||
 CYCN | 13.86M | 3.20 | -2.94 | 3.7% | -264.73% | -62.1% | ||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 |
Compare BCYC vs Peers
Bicycle Therapeutics plc (BCYC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCYC Income Statement
Bicycle Therapeutics plc (BCYC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.06M | 7.14M | 13.8M | 10.39M | 11.7M | 14.46M | 26.98M | 35.27M | 72.59M | 63.5M |
Revenue Growth % | - | 246.41% | 93.4% | -24.72% | 12.58% | 23.65% | 86.52% | 30.76% | 105.77% | 146.85% |
Cost of Goods Sold | 11.87M | 20.76M | 25.54M | 33.15M | 0 | 0 | 156.5M | 172.97M | 0 | 71.03M |
COGS % of Revenue | 576.02% | 290.93% | 185.06% | 319.05% | - | - | 580.13% | 490.34% | - | - |
Gross Profit | -9.81M▲ 0% | -13.63M▼ 38.9% | -11.74M▲ 13.8% | -22.76M▼ 93.9% | 11.7M▲ 151.4% | 14.46M▲ 23.6% | -129.52M▼ 995.5% | -137.69M▼ 6.3% | 72.59M▲ 152.7% | -7.53M▲ 0% |
Gross Margin % | -476.02% | -190.93% | -85.06% | -219.05% | 100% | 100% | -480.13% | -390.34% | 100% | -11.86% |
Gross Profit Growth % | -3541.44% | -38.95% | 13.84% | -93.88% | 151.4% | 23.65% | -995.53% | -6.31% | 152.72% | - |
Operating Expenses | 18.27M | 28.88M | 14.56M | 29.2M | 77.31M | 131.12M | 60.43M | 72.18M | 320.3M | 234.87M |
OpEx % of Revenue | 887.04% | 404.74% | 105.5% | 281.05% | 660.98% | 906.56% | 224% | 204.62% | 441.28% | - |
Selling, General & Admin | 6.41M | 8.12M | 14.56M | 29.2M | 32.44M | 49.51M | 59.83M | 71.46M | 80.02M | 76.67M |
SG&A % of Revenue | 311.02% | 113.8% | 105.5% | 281.05% | 277.29% | 342.3% | 221.8% | 202.59% | 110.24% | - |
Research & Development | 11.87M | 20.76M | 31.64M | 33.15M | 44.88M | 81.61M | 156.5M | 172.97M | 240.28M | 230.13M |
R&D % of Revenue | 576.02% | 290.93% | 229.26% | 319.05% | 383.69% | 564.26% | 580.13% | 490.34% | 331.03% | - |
Other Operating Expenses | -119K | -665K | -31.64M | -33.15M | 0 | 0 | -155.9M | -172.25M | 0 | -1.16M |
Operating Income | -16.21M▲ 0% | -21.75M▼ 34.1% | -26.3M▼ 20.9% | -51.96M▼ 97.6% | -65.62M▼ 26.3% | -116.65M▼ 77.8% | -189.95M▼ 62.8% | -209.87M▼ 10.5% | -247.72M▼ 18.0% | -242.4M▲ 0% |
Operating Margin % | -787.04% | -304.74% | -190.56% | -500.1% | -560.98% | -806.56% | -704.13% | -594.96% | -341.28% | -381.75% |
Operating Income Growth % | -20.15% | -34.13% | -20.94% | -97.57% | -26.29% | -77.78% | -62.83% | -10.49% | -18.03% | - |
EBITDA | -15.88M | -21.04M | -25.34M | -50.68M | -64.21M | -112.96M | -183.4M | -202.69M | -241.3M | -236.48M |
EBITDA Margin % | -770.75% | -294.78% | -183.6% | -487.81% | -548.94% | -781.06% | -679.86% | -574.61% | -332.43% | -372.44% |
EBITDA Growth % | -20.06% | -32.48% | -20.46% | -100.02% | -26.69% | -75.93% | -62.35% | -10.52% | -19.04% | 5.83% |
D&A (Non-Cash Add-back) | 335.56K | 710.8K | 960K | 1.28M | 1.41M | 3.69M | 6.55M | 7.18M | 6.42M | 5.92M |
EBIT | -16.21M | -22.24M | -26.3M | -51.96M | -65.5M | -110.9M | -189.95M | -172.07M | -218.6M | -217.42M |
Net Interest Income | 50K | 169K | 814K | 226K | -2.86M | 2.41M | 10.74M | 32.55M | 28.26M | 18.02M |
Interest Income | 50K | 169K | 814K | 683K | 120K | 5.76M | 14M | 34.28M | 28.46M | 18.23M |
Interest Expense | 0 | 0 | 0 | 457K | 2.98M | 3.34M | 3.26M | 1.73M | 206K | 203K |
Other Income/Expense | -69K | -496K | -4.56M | 226K | -2.86M | 2.41M | 10.74M | 36.08M | 28.91M | 24.78M |
Pretax Income | -16.28M▲ 0% | -22.24M▼ 36.6% | -30.86M▼ 38.8% | -51.73M▼ 67.6% | -68.48M▼ 32.4% | -114.24M▼ 66.8% | -179.21M▼ 56.9% | -173.8M▲ 3.0% | -218.81M▼ 25.9% | -217.62M▲ 0% |
Pretax Margin % | -790.39% | -311.69% | -223.62% | -497.92% | -585.47% | -789.88% | -664.32% | -492.69% | -301.45% | -342.73% |
Income Tax | -23K | -396K | -254K | -724K | -1.66M | -1.52M | 1.46M | -4.76M | 152K | 1.41M |
Effective Tax Rate % | 0.14% | 1.78% | 0.82% | 1.4% | 2.43% | 1.33% | -0.81% | 2.74% | -0.07% | -0.65% |
Net Income | -16.26M▲ 0% | -21.85M▼ 34.4% | -30.61M▼ 40.1% | -51.01M▼ 66.7% | -66.82M▼ 31.0% | -112.72M▼ 68.7% | -180.66M▼ 60.3% | -169.03M▲ 6.4% | -218.96M▼ 29.5% | -219.03M▲ 0% |
Net Margin % | -789.27% | -306.14% | -221.78% | -490.95% | -571.25% | -779.35% | -669.72% | -479.18% | -301.66% | -344.95% |
Net Income Growth % | -20.34% | -34.36% | -40.11% | -66.66% | -30.99% | -68.69% | -60.28% | 6.44% | -29.54% | -7.78% |
Net Income (Continuing) | -16.26M | -21.85M | -30.61M | -51.01M | -66.82M | -112.72M | -180.66M | -169.03M | -218.96M | -219.03M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.22▲ 0% | -1.64▼ 34.4% | -2.77▼ 68.9% | -2.66▲ 4.0% | -2.67▼ 0.4% | -3.80▼ 42.3% | -5.08▼ 33.7% | -2.90▲ 42.9% | -3.16▼ 9.0% | -3.14▲ 0% |
EPS Growth % | -60.53% | -34.43% | -68.9% | 3.97% | -0.38% | -42.32% | -33.68% | 42.91% | -8.97% | -0.64% |
EPS (Basic) | -1.22 | -1.64 | -2.77 | -2.66 | -2.67 | -3.80 | -5.08 | -2.91 | -3.16 | - |
Diluted Shares Outstanding | 13.29M | 13.29M | 11.05M | 19.15M | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M | 69.68M |
Basic Shares Outstanding | 13.29M | 13.29M | 11.05M | 19.15M | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M | 69.68M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BCYC Balance Sheet
Bicycle Therapeutics plc (BCYC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 71.51M | 76.77M | 104.15M | 155.72M | 458.56M | 369.38M | 561.87M | 928.61M | 628.11M | 619.13M |
Cash & Short-Term Investments | 67.66M | 63.38M | 92.12M | 135.99M | 438.68M | 339.15M | 526.42M | 879.52M | 628.11M | 559.47M |
Cash Only | 67.66M | 63.38M | 92.12M | 135.99M | 438.68M | 339.15M | 526.42M | 879.52M | 628.11M | 559.47M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 3M | 11.31M | 7.14M | 14.63M | 11.91M | 21.21M | 24.04M | 35.65M | 35.59M | 40.92M |
Days Sales Outstanding | 531.73 | 578.65 | 188.97 | 514.06 | 371.65 | 535.2 | 325.26 | 368.91 | 178.99 | 293.93 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 9.02M | 11.41M | 13.43M | -35.59M | 18.74M |
Total Non-Current Assets | 2.49M | 4.86M | 6.05M | 5.43M | 21.24M | 41.23M | 33.48M | 28.26M | 89.49M | 33.26M |
Property, Plant & Equipment | 1.36M | 1.82M | 4.35M | 3.61M | 17.79M | 32.77M | 27.68M | 17.19M | 0 | 20.27M |
Fixed Asset Turnover | 1.51x | 3.93x | 3.17x | 2.88x | 0.66x | 0.44x | 0.97x | 2.05x | - | 5.54x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 547K | 547K | 58K | 605K |
Other Non-Current Assets | 1.13M | 3.04M | 1.7M | 1.82M | 3.45M | 8.46M | 5.24M | 10.53M | 89.43M | 12.99M |
Total Assets | 74M▲ 0% | 81.63M▲ 10.3% | 110.19M▲ 35.0% | 161.15M▲ 46.2% | 479.79M▲ 197.7% | 410.61M▼ 14.4% | 595.34M▲ 45.0% | 956.87M▲ 60.7% | 717.6M▼ 25.0% | 652.4M▲ 0% |
Asset Turnover | 0.03x | 0.09x | 0.13x | 0.06x | 0.02x | 0.04x | 0.05x | 0.04x | 0.10x | 0.09x |
Asset Growth % | 525.27% | 10.3% | 35% | 46.24% | 197.73% | -14.42% | 44.99% | 60.73% | -25.01% | -95.85% |
Total Current Liabilities | 9.45M | 8.93M | 8.82M | 23.13M | 36.24M | 53.34M | 69.54M | 67.23M | 56.98M | 48.89M |
Accounts Payable | 2.06M | 1.89M | 1.95M | 1.36M | 2.72M | 6.47M | 13.05M | 15.79M | 9.67M | 5.97M |
Days Payables Outstanding | 63.52 | 33.18 | 27.85 | 15.03 | - | - | 30.44 | 33.33 | - | 59.81 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 4.88M | 0 | 2.76M | 0 |
Deferred Revenue (Current) | 3.98M | 10K | 728K | 10.13M | 19.27M | 20.42M | 24.98M | 10.19M | 0 | 29.68M |
Other Current Liabilities | 148K | 5.42M | 2.58M | 6.39M | 7M | 13.4M | 13.24M | 35.74M | 44.56M | 40.12M |
Current Ratio | 7.57x | 8.60x | 11.81x | 6.73x | 12.65x | 6.92x | 8.08x | 13.81x | 11.02x | 12.66x |
Quick Ratio | 7.57x | 8.60x | 11.81x | 6.73x | 12.65x | 6.92x | 8.08x | 13.81x | 11.02x | 12.66x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 234.12 |
Total Non-Current Liabilities | 111.73M | 142.52M | 8.18M | 42.56M | 97.3M | 86.48M | 154.88M | 96.58M | 50.64M | 49.19M |
Long-Term Debt | 0 | 0 | 0 | 14.51M | 29.87M | 30.32M | 30.7M | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 1.25M | 426K | 12.08M | 10.88M | 9.38M | 3.99M | 14.77M | 32.17M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 101.25M | 127.9M | 2M | 2.61M | 3.28M | 3.83M | 4.58M | 1.12M | 363K | 973K |
Total Liabilities | 121.19M | 151.45M | 17M | 65.69M | 133.54M | 139.83M | 224.41M | 163.81M | 107.62M | 98.08M |
Total Debt | 0 | 0 | 1.89M | 15.78M | 44.34M | 44.33M | 44.96M | 9.49M | 17.52M | 13.87M |
Net Debt | -67.66M | -63.38M | -90.23M | -120.22M | -394.34M | -294.83M | -481.47M | -870.03M | -610.59M | -545.6M |
Debt / Equity | - | - | 0.02x | 0.17x | 0.13x | 0.16x | 0.12x | 0.01x | 0.03x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.31x |
Interest Coverage | - | - | - | -113.70x | -21.95x | -33.16x | -58.21x | -99.46x | -1061.17x | -1071.02x |
Total Equity | -47.18M▲ 0% | -69.83M▼ 48.0% | 93.2M▲ 233.5% | 95.46M▲ 2.4% | 346.25M▲ 262.7% | 270.78M▼ 21.8% | 370.93M▲ 37.0% | 793.06M▲ 113.8% | 609.98M▼ 23.1% | 554.32M▲ 0% |
Equity Growth % | -688.04% | -47.99% | 233.47% | 2.43% | 262.72% | -21.8% | 36.98% | 113.8% | -23.09% | -97.24% |
Book Value per Share | -3.55 | -5.25 | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | 13.62 | 8.80 | 7.95 |
Total Shareholders' Equity | -47.18M | -69.83M | 93.2M | 95.46M | 346.25M | 270.78M | 370.93M | 793.06M | 609.98M | 554.32M |
Common Stock | 5K | 10K | 227K | 266K | 384K | 387K | 550K | 890K | 894K | 899K |
Retained Earnings | -48.1M | -69.94M | -100.55M | -151.56M | -218.38M | -331.1M | -511.76M | -680.79M | -899.75M | -960.58M |
Treasury Stock | -837K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 69K | -1.75M | -1.53M | -3.19M | -3.39M | 387K | -1.3M | 119K | -3.5M | -5.28M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCYC Cash Flow Statement
Bicycle Therapeutics plc (BCYC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.42M | -26.08M | -28.61M | -17.79M | -14.79M | -86.11M | -60.63M | -164.72M | -249.68M | -228.9M |
Operating CF Margin % | -68.69% | -365.44% | -207.33% | -171.21% | -126.48% | -595.39% | -224.75% | -466.97% | -343.97% | - |
Operating CF Growth % | 87.44% | -1742.97% | -9.72% | 37.83% | 16.84% | -482.07% | 29.59% | -171.7% | -51.57% | -219.91% |
Net Income | -16.26M | -21.85M | -30.61M | -51.01M | -66.82M | -112.72M | -180.66M | -169.03M | -218.96M | -219.03M |
Depreciation & Amortization | 332K | 712K | 960K | 1.28M | 1.41M | 3.69M | 6.55M | 7.17M | 0 | -511.27K |
Stock-Based Compensation | 515K | 1.02M | 3.08M | 6.51M | 12.08M | 26.78M | 32.48M | 38.08M | 0 | -2.67M |
Deferred Taxes | 119K | 0 | 0 | -673K | -1.67M | -4.98M | 3.31M | -5.23M | 0 | 1.08M |
Other Non-Cash Items | 856K | 665K | 5.38M | 751K | 2.14M | 442K | 1.04M | -2.26M | 45.21M | -30.75M |
Working Capital Changes | 13.02M | -6.63M | -7.43M | 25.35M | 38.06M | 672K | 76.66M | -33.46M | -75.93M | 22.76M |
Change in Receivables | -1.42M | -400K | 4.91M | -2.15M | 4.54M | -11.35M | -1.2M | -11.95M | 2.9M | 3.41M |
Change in Inventory | 0 | -2.12M | -2.55M | 4.16M | -4.79M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 67K | -169K | 220K | -663K | 1.2M | 2.56M | 8M | 3.1M | -6.89M | 1.2M |
Cash from Investing | -1.11M | -1.19M | -1.55M | -1.2M | -2.03M | -18.99M | -2.93M | -1.24M | -2.35M | -2.46M |
Capital Expenditures | -1.11M | -1.19M | -1.55M | -1.2M | -2.03M | -18.99M | -2.93M | -1.24M | -2.36M | -106.68K |
CapEx % of Revenue | 54.03% | 16.62% | 11.27% | 11.55% | 17.35% | 131.28% | 10.86% | 3.5% | 3.25% | 0.17% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.49K | -2.35M |
Cash from Financing | 57.88M | 25.43M | 58.44M | 62.84M | 320.73M | 6.69M | 250.03M | 519.75M | -131K | -143.84K |
Debt Issued (Net) | 0 | 0 | 0 | 15M | 15M | 0 | 0 | -31.91M | 0 | -23K |
Equity Issued (Net) | 57.88M | 25.43M | 58.29M | 48.14M | 298.54M | 5.7M | 249.34M | 544.13M | 37.09K | 9.99K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -576K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1K | 1K | 149K | -301K | 7.18M | 989K | 682K | 7.53M | -168.09K | -130.84K |
Net Change in Cash | 58.26M▲ 0% | -4.28M▼ 107.4% | 28.74M▲ 771.0% | 43.87M▲ 52.7% | 302.69M▲ 589.9% | -99.53M▼ 132.9% | 187.82M▲ 288.7% | 353.1M▲ 88.0% | -251.35M▼ 171.2% | -232.95M▲ 0% |
Free Cash Flow | -2.53M▲ 0% | -27.26M▼ 978.5% | -30.17M▼ 10.7% | -18.99M▲ 37.1% | -16.82M▲ 11.4% | -105.1M▼ 524.7% | -63.56M▲ 39.5% | -165.96M▼ 161.1% | -252.61M▼ 52.2% | -229.01M▲ 0% |
FCF Margin % | -122.72% | -382.06% | -218.59% | -182.76% | -143.83% | -726.67% | -235.61% | -470.47% | -348.02% | -360.66% |
FCF Growth % | 78.04% | -978.48% | -10.65% | 37.06% | 11.4% | -524.69% | 39.53% | -161.12% | -52.21% | -25.51% |
FCF per Share | -0.19 | -2.05 | -2.73 | -0.99 | -0.67 | -3.54 | -1.79 | -2.85 | -3.65 | -3.29 |
FCF Conversion (FCF/Net Income) | 0.09x | 1.19x | 0.93x | 0.35x | 0.22x | 0.76x | 0.34x | 0.97x | 1.14x | 1.05x |
Interest Paid | 0 | 0 | 0 | 378K | 2.52M | 2.79M | 2.75M | 1.37M | 0 | -22K |
Taxes Paid | 0 | 73K | 117K | 124K | 73K | 2.23M | 562K | 792K | 0 | 0 |
BCYC Key Ratios
Bicycle Therapeutics plc (BCYC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -261.92% | -54.08% | -30.25% | -36.53% | -56.31% | -29.04% | -31.21% | -35.74% |
Return on Invested Capital (ROIC) | - | - | -663.67% | - | - | - | - | - | - | 1201.09% |
Gross Margin | -476.02% | -190.93% | -85.06% | -219.05% | 100% | 100% | -480.13% | -390.34% | 100% | -11.86% |
Net Margin | -789.27% | -306.14% | -221.78% | -490.95% | -571.25% | -779.35% | -669.72% | -479.18% | -301.66% | -344.95% |
Debt / Equity | - | - | 0.02x | 0.17x | 0.13x | 0.16x | 0.12x | 0.01x | 0.03x | 0.03x |
Interest Coverage | - | - | - | -113.70x | -21.95x | -33.16x | -58.21x | -99.46x | -1061.17x | -1071.02x |
FCF Conversion | 0.09x | 1.19x | 0.93x | 0.35x | 0.22x | 0.76x | 0.34x | 0.97x | 1.14x | 1.05x |
Revenue Growth | - | 246.41% | 93.4% | -24.72% | 12.58% | 23.65% | 86.52% | 30.76% | 105.77% | 146.85% |
Related:BCYC Dividend History·BCYC Revenue History·BCYC Price History·BCYC P/E History·BCYC Financial Ratios·BCYC Institutional Holders
BCYC SEC Filings & Documents
Bicycle Therapeutics plc (BCYC) SEC filings — annual & quarterly reports (10-K, 10-Q)
BCYC Frequently Asked Questions
Bicycle Therapeutics plc (BCYC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bicycle Therapeutics plc (BCYC) reported $63.5M in revenue for fiscal year 2025.
Bicycle Therapeutics plc (BCYC) grew revenue by 105.8% over the past year. This is strong growth.
Bicycle Therapeutics plc (BCYC) reported a net loss of $219.0M for fiscal year 2025.
Dividend & Returns
Bicycle Therapeutics plc (BCYC) has a return on equity (ROE) of -31.2%. Negative ROE indicates the company is unprofitable.
Bicycle Therapeutics plc (BCYC) had negative free cash flow of $229.0M in fiscal year 2025, likely due to heavy capital investments.